Paper Details

  1. Home
  2. Paper Details

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

Author: ArrizabalagaJ, ClotetB G, CrucetaA, DalmauD, GallartT, GarcíaF, GatellJ M, Gomez-SirventJ L, GrauI, KnobelH, MiróJ M, O'BrienW A, PodzamczerD, PumarolaT, RomeuJ, SambeatM A

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Current guidelines suggest starting antiretroviral treatment for HIV infection when the amount of virus in the blood is above 5,000-10,000 copies per milliliter and the number of CD4 cells is above 500 per microliter. However, there is ongoing debate about whether it is better to start treatment earlier or later in the course of the disease.
Paper Details　
Original Abstract of the Article :
Most current guidelines state that antiretroviral therapy should be considered for HIV-infected patients with plasma HIV RNA > 5000-10000 copies/ml and CD4 cells > 500 x 10(6) cells/l. However, there is increasing concern about whether this is the optimal point to begin treatment or whether it is be...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/00002030-199912030-00009

データ提供：米国国立医学図書館（NLM）

Timing is Key: Exploring the Optimal Time for Antiretroviral Therapy in HIV-1

The treatment of HIV-1 infection has made remarkable strides in recent years, but the optimal time to initiate antiretroviral therapy remains a subject of ongoing debate. This study delves into this crucial question, comparing the effectiveness of starting treatment in very early stages of HIV-1 infection. The researchers conducted a randomized study to assess the outcomes of triple antiretroviral therapy, double therapy, and no treatment in patients with early-stage HIV-1.

A Critical Look at Early Intervention

The study's findings challenge the prevailing guidelines, suggesting that early initiation of antiretroviral therapy might not be the most advantageous approach for all patients. The researchers found that delaying treatment until more advanced stages could potentially lead to better outcomes.

A Personalized Approach to HIV-1 Treatment

This research underscores the importance of a personalized approach to HIV-1 treatment, considering each patient's individual circumstances and disease progression. Healthcare providers should carefully evaluate each patient's situation to determine the most appropriate timing for antiretroviral therapy.

Dr.Camel's Conclusion

Like a desert traveler carefully planning their route, researchers are meticulously exploring the optimal timing for antiretroviral therapy in HIV-1. This study's findings highlight the need for a personalized approach to treatment, recognizing that a one-size-fits-all approach might not be the most effective strategy.

Date :
  1. Date Completed 2000-01-24
  2. Date Revised 2019-07-18
Further Info :

Pubmed ID

10597779

DOI: Digital Object Identifier

10.1097/00002030-199912030-00009

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.